Lentigen Corporation, founded in 2004, is a biologics company headquartered in Gaithersburg, Maryland. The company’s focus is on developing and commercializing biotherapeutics and vaccines to treat human diseases, and to become a leader in the development of biologic products. Lentigen’s proprietary lentiviral vector (LV) technology is recognized by the scientific community as an efficient method for reprogramming cells by delivering genetic sequence information to them.

Lentigen’s mission, according to its website, is “advancing biomedicine and improving human health by the development of biotherapeutics, vaccines, protein therapeutics, and tools for discovery research.” Lentigen’s management team includes Tim Ravenscroft, chief executive officer; Boro Dropulic, PhD, MBA, founder and chief scientific officer; and James H. Meade, PhD, CLP, vice president, Corporate Development; and David S. Wetherell, chairman.

Lentigen’s business strategy ...

  • Loading...
locked icon

Sign in to access this content

Get a 30 day FREE TRIAL

  • Watch videos from a variety of sources bringing classroom topics to life
  • Read modern, diverse business cases
  • Explore hundreds of books and reference titles